Last reviewed · How we verify
Inotuzumab Ozogamicin+Standard Maintenance Therapy (inotuzumab-ozogamicin-standard-maintenance-therapy)
Inotuzumab Ozogamicin+Standard Maintenance Therapy (generic name: inotuzumab-ozogamicin-standard-maintenance-therapy) is a Monoclonal antibody drug developed by Pfizer Inc.. It is currently in Phase 3 development.
Inotuzumab ozogamicin targets CD22 on B-cell leukemia cells, delivering a cytotoxic agent to induce cell death.
At a glance
| Generic name | inotuzumab-ozogamicin-standard-maintenance-therapy |
|---|---|
| Sponsor | Pfizer Inc. |
| Modality | Monoclonal antibody |
| Phase | Phase 3 |
Mechanism of action
Inotuzumab ozogamicin binds to CD22 on cancerous B-cells, releasing a potent toxin that disrupts cellular processes and leads to apoptosis, effectively targeting the CD22 pathway.
Approved indications
Common side effects
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Inotuzumab Ozogamicin+Standard Maintenance Therapy CI brief — competitive landscape report
- Inotuzumab Ozogamicin+Standard Maintenance Therapy updates RSS · CI watch RSS
- Pfizer Inc. portfolio CI
Frequently asked questions about Inotuzumab Ozogamicin+Standard Maintenance Therapy
What is Inotuzumab Ozogamicin+Standard Maintenance Therapy?
Inotuzumab Ozogamicin+Standard Maintenance Therapy (inotuzumab-ozogamicin-standard-maintenance-therapy) is a Monoclonal antibody drug developed by Pfizer Inc..
How does Inotuzumab Ozogamicin+Standard Maintenance Therapy work?
Inotuzumab ozogamicin targets CD22 on B-cell leukemia cells, delivering a cytotoxic agent to induce cell death.
Who makes Inotuzumab Ozogamicin+Standard Maintenance Therapy?
Inotuzumab Ozogamicin+Standard Maintenance Therapy is developed by Pfizer Inc. (see full Pfizer Inc. pipeline at /company/pfizer).
What is the generic name of Inotuzumab Ozogamicin+Standard Maintenance Therapy?
inotuzumab-ozogamicin-standard-maintenance-therapy is the generic (nonproprietary) name of Inotuzumab Ozogamicin+Standard Maintenance Therapy.
What development phase is Inotuzumab Ozogamicin+Standard Maintenance Therapy in?
Inotuzumab Ozogamicin+Standard Maintenance Therapy is in Phase 3.